Dilated Cardiomyopathy Secondary to Toxicity from Anthracycline Chemotherapy in a Patient with a History of Acute Lymphoblastic Leukemia: A Case Report
Main Article Content
Abstract
Dilated cardiomyopathy is defined by presence of left ventricular or biventricular dilation and left systolic dysfunction in absence of hypertension, coronary disease, or valvular disease that would justify it. Its causes can be divided into two large groups: those of genetic origin and those of nongenetic origin, which include infectious, toxic, and autoimmune disease causes, among others. Its natural course varies significantly based on the different etiologies and its diagnosis can influence the disease's management and prognosis.
Clinical case: 29-year-old male, with a history of having suffered from Acute Lymphoblastic Leukemia at the age of 4 with complete remission of the disease demonstrated at that time by bone marrow aspirate and immunophenotype, having been treated with anthracyclines. On this occasion, he attended due to the presence of sudden onset dyspnea and hemoptysis, for which in the first instance, due to the previously mentioned history, an attempt was made to rule out pulmonary thromboembolism with chest Angio tomography, which was corroborated by said study and demonstrating the presence of two intracavitary thrombi. Therefore, a transthoracic echocardiogram was performed, highlighting severe dilation of the left ventricle. Management for heart failure was adjusted based on structural alteration demonstrated by echocardiography, with favorable clinical evolution.
Conclusions: The natural history of dilated cardiomyopathy is not easy to establish due to the wide heterogeneity of its etiology and the different rates of progression depending on it. In some cases, there may be functional recovery after acute myocardial damage, for example, in cardiomyopathy induced by tachycardia or in that induced by cardiotoxic drugs. In other cases, stabilization of the disease and systolic dysfunction and, in others, sudden death may be observed.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. García A, Pérez M, Díaz B, González JR. Miocardiopatía dilatada. Medicine - Programa de Formación. Médica Continuada Acreditando. 2021; 13 (42): 2447 - 2458.
DOI: https://doi.org/10.1016/j.med.2021.09.021
II. Japp et al. The Diagnosis and Evaluation of DCM. JACC VOL. 67, NO. 25, 2016. JUNE 28, 2016:2996 – 3010.
DOI: https://doi.org/10.1016/j.jacc.2016.03.590
III. Pérez-Serra A et al. Implementing a New Algorithm for Reinterpretation of Ambiguous Variants in Genetic Dilated Cardiomyopathy, International Journal of Molecular Sciences, 25, 7, (3807), (2024).
DOI: https://doi.org/10.3390/ijms25073807
IV. Pidaparti M, Geddes GC, Durbin MD. Clinical Genetic and Genomic Testing in Congenital Heart Disease and Cardiomyopathy. Journal of Clinical Medicine, 13, 9, (2544), (2024).
DOI: https://doi.org/10.3390/jcm13092544
V. Cannata A, Frabris E, Merlo M, Artico J, Gentile P et al. Sex Differences in the Long-term Prognosis of Dilated Cardiomyopathy. Canadian Journal of Cardiology. Volume 36, Issue 1, January 202, Pages 37 - 44.
DOI: https://doi.org/10.1016/j.cjca.2019.05.031
VI. Begay et al. Filamin C Truncations Alter Cellular Adhesion. JACC. 2018; 4 (4): 504 – 14.
DOI: https://doi.org/10.1016/j.jacep.2017.12.003
VII. G. Curigliano et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. Volume 31, Issue 2, 2020.
DOI: https://doi.org/10.1016/j.annonc.2019.10.023
VIII. Costabel JP, Mandó F, Avegliano G. Miocardiopatía dilatada: ¿cuándo y cómo proceder a la investigación etiológica? Rev Urug Cardiol 2018; 33: 343-349.
IX. Rajiah et al. Nonischemic Myocardial Disease with Clinical Manifestations. Journal of the American College of Radiology. 2021; 18: 5S.
DOI: https://doi.org/10.1016/j.jacr.2021.01.019
X. Arbelo E, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44, (37): 3503–3626.
DOI: https://doi.org/10.1093/eurheartj/ehad194
XI. Pinto YM, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8.
XII. Towbin et al. Evaluation, Risk Stratification, and Management of ACM. Heart Rhythm, Vol 16, No 11, November 2019.
DOI: https://doi.org/10.1016/j.hrthm.2019.05.007
XIII. Escobar L, Ochoa JP, Mirelis JG et al. Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2021 Oct, 78 (17) 1682-1699.
XIV. Wilde AM, et al. Expert Consensus Statement on the state of genetic testing for cardiac diseases. EP Europace. 2022; 24 (8): 1307–1367. DOI: https://doi.org/10.1093/europace/euac030
XV. Amor A, Guzzo G, González E et al. Impacto pronóstico y factores predictores de la recuperación de la fracción de eyección en pacientes con miocardiopatía dilatada alcohólica. Rev Esp Cardiol. 2018;71:612-9.